Xcovery Announces Presentation of Clinical Data at Upcoming ASCO Annual Meeting
Phase I Study Is First-in-Human Trial of an Oral VEGFR Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Solid Tumors
(firmenpresse) - WEST PALM BEACH, FL -- (Marketwire) -- 05/18/12 -- , a developer of next-generation targeted therapeutics for cancer, today announced that investigators will present data from its Phase 1 clinical study which evaluated X-82, an oral VEGFR tyrosine kinase inhibitor (TKI), in patients with advanced solid tumors.
The data will be presented in a poster presentation at the American Society of Clinical Oncology's (ASCO) Annual Meeting taking place on Friday, June 1 through Tuesday, June 5, 2012 in Chicago.
A Phase I First-in-Human Trial of an Oral VEGFR Tyrosine Kinase Inhibitor (TKI), X-82, in Patients with Advanced Solid Tumors
Monday, June 4, 2012: 8:00 AM - 12:00 PM, CT
#3041
S Hall, A2
The poster will be made available for viewing on the company's website, , following the public presentation.
VEGFR tyrosine kinase inhibitors have demonstrated benefit in a variety of cancers. However, it has been well documented that the dosage and use of this class in combination with other therapies has been limited by side effects.
Xcovery's lead clinical candidate, X-82, is a novel, potent, oral dual VEGFR/PDGFR inhibitor, designed to minimize side effects. The preliminary Phase 1 data described in this poster presentation suggests that X-82 has unique pharmacokinetic and pharmacodynamic properties which differentiate it from competitive products in development and on the market.
Xcovery is a clinical-stage company focused on the development of next-generation targeted therapeutics for cancer. Founded by Sheridan G. Snyder and Chris Liang, PhD, Xcovery's vision is to successfully develop innovative oncology therapies to optimize patient outcomes. Through innovative drug design, Xcovery has developed a comprehensive pipeline of oncology therapies that target a wide range of advanced tumors. X-82 was developed by Tyrogenex, an company, funded by Biocatalyst International.
Amanda Murphy or Donna LaVoie
LaVoie Group
Office: 978.745.4200 x107/ x103
Cheryl Calhoun
Vice President
(561) 835-9356
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2012 - 09:12 Uhr
Sprache: Deutsch
News-ID 1116063
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
WEST PALM BEACH, FL
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Xcovery Announces Presentation of Clinical Data at Upcoming ASCO Annual Meeting
"
steht unter der journalistisch-redaktionellen Verantwortung von
Xcovery (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
